Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
245.6 EUR | -0.14% | -.--% | -.--% |
Apr. 25 | The specter of stagflation rears its ugly head again | |
Apr. 25 | ROCHE : Barclays lowers target price | CF |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's enterprise value to sales, at 3.14 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 193B | - | ||
+24.17% | 556B | B | ||
-6.33% | 354B | C+ | ||
+19.90% | 331B | B- | ||
+7.95% | 296B | C+ | ||
+13.45% | 233B | B+ | ||
+6.04% | 201B | B- | ||
-12.26% | 143B | C+ | ||
-6.47% | 144B | C+ | ||
+2.07% | 123B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ROG Stock
- RHO5 Stock
- Ratings Roche Holding AG